Juno, Editas to collaborate on CAR T therapies

Juno Therapeutics Inc. (NASDAQ:JUNO) and Editas Medicine (Cambridge, Mass.) partnered to develop chimeric antigen receptor (CAR) T cell and T cell receptor ( TCR) therapies for cancer. The partners will develop three undisclosed programs using Juno's CAR and TCR technologies and Editas' gene editing platform that uses CRISPR/ Cas9 ( CRISPR-associated protein 9).

Editas will receive $25 million up front and is eligible for $230 million in milestones for each research program, plus tiered royalties. Juno also will provide Editas with up to $22 million in total research funding over five years. ...